US › Healthcare

Fulcrum Therapeutics Inc (FULC)

US · Healthcare · Biotechnology

$3.65-0.54%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-26.2M

EPS

$-0.29

EPS estimate

$-0.21

EPS came in at -0.29 against a street estimate of -0.21 — a miss of 36.5%.

Key statistics

Market cap

$288.0M

Forward P/E

0.0

P/B

0.94

Book value

$4.07

EPS (TTM)

$-1.21

52-week high

$15.74

52-week low

$2.83

50-day MA

$3.78

200-day MA

$6.40

Beta

2.63

Analyst view

Analysts rate Fulcrum Therapeutics Inc a hold (0 buy, 4 hold, 1 sell out of 5) with an average price target of $3.67.

Shareholding

Insiders

3.35%

Institutions

102.91%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	14.34%
BlackRock Inc	11.55%
EcoR1 Capital, LLC	8.58%
TANG CAPITAL MANAGEMENT LLC	8.54%
Suvretta Capital Management, LLC	4.82%
D. E. Shaw & Co LP	3.99%
Citadel Advisors Llc	3.54%
Vanguard Capital Management, LLC	3.53%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fulcrum Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.